D. L. Diuguid

Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy.

B. Furie, B. Furie, M. Jacobs, 1990, Blood.

Molecular defects of factor IX Chicago-2 (Arg 145----His) and prothrombin Madrid (Arg 271----cys): arginine mutations that preclude zymogen activation.

B. Furie, B. Furie, M. Rabiet, 1989, Blood.

Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.

B. Furie, H. Liebman, D. L. Diuguid, 1986, Proceedings of the National Academy of Sciences of the United States of America.

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: July 2021 update on postdischarge thromboprophylaxis

E. Akl, H. Schünemann, R. Mustafa, 2021, Blood Advances.

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients

E. Akl, R. Mustafa, S. Kahn, 2021, Blood Advances.

Factor IX San Dimas. Substitution of glutamine for Arg-4 in the propeptide leads to incomplete gamma-carboxylation and altered phospholipid binding properties.

B. Furie, J. Ware, D. Stafford, 1989, The Journal of biological chemistry.